A 42-year-old man from Bangalore with Stage IIA classical Hodgkin lymphoma (lymphocyte-rich subtype) completes 4 cycles of ABVD chemotherapy. Post-treatment PET-CT shows complete metabolic response (CMR) in all previously involved sites with Deauville score 1. What is the most appropriate next step in management?
A. Involved-field radiotherapy (IFRT) 30 Gy to all previously involved sites
B. Observation with clinical review every 3 months and repeat PET-CT at 6 months
C. Consolidation with autologous stem cell transplantation (ASCT)
D. Salvage chemotherapy with escalated BEACOPP or DHAP (dexamethasone, high-dose cytarabine, cisplatin)
Explanation
Clinical Context
This patient has achieved complete metabolic response (CMR) after standard chemotherapy for early-stage cHL. The Deauville score of 1 (no uptake above mediastinal blood pool) indicates excellent treatment response and predicts favorable long-term outcome.
Post-Treatment Management in cHL with CMR
Key Point
Patients with complete metabolic response (Deauville score 1–2) after chemotherapy for early-stage cHL do NOT require consolidation radiotherapy or salvage therapy. Observation with clinical surveillance is the standard of care.
High-YieldNEET PG
Modern risk-adapted treatment in cHL emphasizes de-escalation: patients achieving CMR after chemotherapy have excellent prognosis (>95% 5-year PFS) and do not benefit from additional therapy.
Rationale for Observation
1.
CMR predicts excellent outcome — Deauville score 1–2 after chemotherapy is associated with >95% 5-year PFS in early-stage cHL
2.
Avoids late toxicity — omitting radiotherapy reduces risk of secondary malignancies, cardiac dysfunction, and pulmonary fibrosis
3.
No role for consolidation in CMR — ASCT is reserved for chemotherapy-refractory or relapsed disease, not for responding patients
4.
Salvage therapy unnecessary — escalated chemotherapy or DHAP are indicated only for progressive disease or relapse, not for CMR
Surveillance Strategy
Clinical examination — every 3 months for first 2 years, then every 6 months
Repeat imaging — PET-CT at 6 months post-treatment only if clinically indicated (new symptoms, rising tumor markers); routine surveillance imaging is not recommended
Long-term follow-up — annual clinical assessment for ≥5 years to detect relapse or late toxicities
Clinical Pearl
The paradigm shift in cHL management is toward "response-adapted" therapy: de-escalation in chemotherapy-responsive patients (CMR) and escalation only in non-responders. This maximizes cure while minimizing late effects.
Why Not the Other Options?
Table
Option
Why Incorrect
IFRT after CMR
Radiotherapy consolidation is not indicated in patients with CMR after chemotherapy. It increases late toxicity without improving PFS and is considered over-treatment.
Salvage chemotherapy (BEACOPP/DHAP)
Salvage regimens are reserved for chemotherapy-refractory or relapsed disease. A patient in CMR does not require salvage therapy; it is unnecessary and harmful.
ASCT
Autologous stem cell transplantation is indicated only for chemotherapy-refractory disease or relapse, not for primary therapy in responding patients. ASCT in CMR patients offers no benefit.
Harrison 21e Ch 104
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
